Leo Fitzpatrick is the Assistant Dean of Research at the California Northstate University College of Pharmacy. He began his scientific career, by doing a post-doctoral fellowship at the University of Texas Medical School (Houston). Subsequently, Dr. Fitzpatrick was involved in drug discovery and development at three pharmaceutical companies. At Otsuka Pharmaceutical Inc. (Maryland Research Institute), he contributed to the development of Tetomilast, which advanced into phase 3 clinical trials for Inflammatory Bowel Disease (IBD). Subsequently, Dr. Fitzpatrick began a 10 year (2003-2013) faculty position at the Penn State College of Medicine (Hershey, PA). While at Penn State, he continued ongoing research related to IBD, infectious colitis and arthritis. His research collaborations resulted in the funding of 15 academic-related grants/contracts with pharmaceutical/biotechnology companies. While at Penn State, Dr. Fitzpatrick collaborated with a German company (4SC AG). This collaboration contributed to the development of Vidofludimus (a novel immunosuppressive drug), which has entered phase 2 clinical trials for IBD in Europe. He has served on the editorial board of World Journal of Gastrointestinal PathoPhysiology, and Pharmacy & Pharmacology International Journal. Dr. Fitzpatrick has also served on the scientific advisory board for Baxter Health Care. His research interests are in IBD, Infectious Colitis and Rheumatoid Arthritis. He has published 54 original research articles, as well as approximately 70 conference-related abstracts. Dr. Fitzpatrick has taught graduate and medical student classes in pharmacology, immunology and GI PBL at the Penn State College of Medicine, as well as classes in pathophysiology and immunology at the California Northstate University College of Pharmacy.

Pharmacy